Day: March 27, 2024

Aligos Therapeutics Presents Positive Clinical Data at APASL 2024 from ALG-055009 and ALG-000184 Phase 1 Studies

Written by Customer Service on March 27, 2024. Posted in Public Companies.

SOUTH SAN FRANCISCO, Calif., March 27, 2024 (GLOBE NEWSWIRE) — Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced three oral presentations and one poster presentation at the 33rd Annual Meeting of the Asian Pacific Association for the Study of the Liver (APASL) 2024, being held March 27-31, 2024 in Kyoto, Japan. The poster presentation highlights ALG-055009 Phase 1 data that showed multiple-ascending doses (MAD) over 14 days in hyperlipidemic subjects produced favorable, dose-dependent pharmacodynamic effects on atherogenic lipids and sex hormone binding globulin (SHBG), an indicator of target engagement in the liver. The three oral presentations provide interim data from...

ZimVie to Participate in the 23rd Annual Needham Virtual Healthcare Conference

Written by Customer Service on March 27, 2024. Posted in Public Companies.

WESTMINSTER, Colo., March 27, 2024 (GLOBE NEWSWIRE) — ZimVie Inc. (Nasdaq: ZIMV), a global life sciences leader in the dental and spine markets, today announced management will participate in the upcoming 23rd Annual Needham Virtual Healthcare Conference. Management will be presenting on Wednesday, April 10th, 2024 at 3:00 p.m. Eastern Time / 12:00 p.m. Pacific Time. A live webcast of the event, as well as an archived recording will be available on the “Investors” section of the company’s website at: www.zimvie.com. The webcast will be archived and available for replay for at least 90 days after the event. About ZimVieZimVie is a global life sciences leader in the dental and spine markets that develops, manufactures, and delivers a comprehensive portfolio of products and solutions designed to treat a wide range of spine pathologies...

Proposals of the Nomination and Remuneration Committee of Sampo plc’s Board of Directors to the Annual General Meeting

Written by Customer Service on March 27, 2024. Posted in Public Companies.

SAMPO PLC STOCK EXCHANGE RELEASE 27 March 2024 at 1:59 pmProposals of the Nomination and Remuneration Committee of Sampo plc’s Board of Directors to the Annual General Meeting The Nomination and Remuneration Committee of Sampo plc’s Board of Directors has made proposals for the remuneration, number, and members of the Board of Directors to the Annual General Meeting to be held on 25 April 2024. The Nomination and Remuneration Committee of the Board of Directors proposes to the Annual General Meeting that the following annual fees be paid until the close of the next Annual General Meeting:the Chair of the Board be paid EUR 235,000 (prev. EUR 228,000) the Vice Chair of the Board be paid EUR 135,000 (prev. EUR 131,000) each member of the Board be paid EUR 104,000 (prev. EUR 101,000) the Chair of the Audit...

Fuel Doctor: Revoltz Initiates on $2.7 Million Exclusive Distribution Agreement with First Batch Production of 50 PORTO Micro-Mobility EVs

Written by Customer Service on March 27, 2024. Posted in Public Companies.

Following production completion, Revoltz sets up for delivery in accordance with its distribution agreement, aiming to sell 150 vehicles in the first year of the agreement Tel Aviv, Israel, March 27, 2024 (GLOBE NEWSWIRE) — Fuel Doctor Holdings, Inc. (OTC: FDOC), a Delaware corporation (“Fuel Doctor”), announced today that Revoltz Ltd. (“Revoltz”) which is 19.9% held by Charging Robotics Ltd., Fuel Doctor’s wholly-owned subsidiary (“Charging Robotics” and together with Fuel Doctor, the “Company”), announced the completion of its first production batch of 50 units of its micro-mobility electric vehicle (“EVs”) for the last-mile delivery market, “PORTO,” Revoltz’s flagship model. Completing the production is a significant step in Revoltz’s preparation for its first shipment in accordance with the distribution agreement it signed...

Medigus: Revoltz Initiates on Exclusive Distribution Agreement of $2.7 Million in Revenues and Completes the Production of the First 50 PORTO Micro-Mobility EVs

Written by Customer Service on March 27, 2024. Posted in Public Companies.

Following completion of initial production, Revoltz sets up for delivery in accordance with its distribution agreement (the “Agreement”), aiming to sell 150 vehicles in the first year of the Agreement Tel Aviv, Israel, March 27, 2024 (GLOBE NEWSWIRE) — Medigus Ltd. (Nasdaq: MDGS), a technology company engaged in advanced medical solutions, innovative internet technologies and electric vehicle (“EV”) and charging solutions, announced today that Revoltz Ltd, its EV joint venture, 19.9% owned by its subsidiary Fuel Doctor Holdings, Inc. (67.15%), completed its first production batch of 50 units of its micro-mobility electric vehicle, ‘PORTO’. The completion of production is a significant step in enabling Revoltz to prepare for shipment of units in accordance with the Agreement signed over the past year. During 2023, Revoltz and a...

Form 8.3 – [abrdn EUROPEAN LOGISTICS INCOME PLC – 26 03 2024] – (CGWL)

Written by Customer Service on March 27, 2024. Posted in Mergers And Acquisitions.

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION(a) Full name of discloser: CANACCORD GENUITY WEALTH LIMITED (for Discretionary clients)(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree abrdn EUROPEAN LOGISTICS INCOME PLC(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e) Date...

Altimmune Announces Positive Lean Mass Preservation Data for Pemvidutide and Reports Fourth Quarter and Full Year 2023 Financial Results

Written by Customer Service on March 27, 2024. Posted in Earnings Releases And Operating Results.

Body composition study showed lean mass preservation, with only 25.5% of weight loss derived from lean mass Enrollment ongoing in IMPACT Phase 2b trial of pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis (MASH), with topline 24-week data expected Q1 2025 Preclinical study results showed a direct anti-fibrotic effect of pemvidutide in anon-steatotic model of liver fibrosis Cash, cash equivalents and short-term investments of $198.0 million at December 31, 2023 Webcast to be held today, March 27, 2024, at 8:30 am ET GAITHERSBURG, Md., March 27, 2024 (GLOBE NEWSWIRE) — Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced financial results for the fourth quarter and full year ended December 31, 2023, and provided a business update. “We are extremely pleased with the results of the...

Gamida Cell Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Company Update

Written by Customer Service on March 27, 2024. Posted in Earnings Releases And Operating Results.

Company announces commencement of restructuring process supported by Highbridge Capital Management Continued progress of launch of Omisirge® (omidubicel-onlv), with the delivery of six units in 2023, as well as significant transplant center onboarding Company to host conference call today at 8:30 a.m. ET BOSTON, March 27, 2024 (GLOBE NEWSWIRE) — Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today provided a business update and reported financial results for the fourth quarter and full year ended December 31, 2023. The company announced today that it has entered into a Restructuring Support Agreement (RSA) with certain funds managed by Highbridge Capital Management, LLC (collectively, “Highbridge”), the company’s principal lender. Contemplated under the terms of the RSA,...

VERB’s MARKET.live Enters Into Formal Partnership With TikTok for Livestream Shopping Services

Written by Customer Service on March 27, 2024. Posted in Public Companies.

MARKET.live’s Official TikTok Shop Partner Designation Underscores A New, Expanded Business Building Relationship LOS ALAMITOS, Calif. and LAS VEGAS, March 27, 2024 (GLOBE NEWSWIRE) — Verb Technology Company, Inc. (Nasdaq: VERB) (“VERB” or the “Company”), the force behind MARKET.live, the popular livestream social shopping platform, announces it has entered into a formal partnership with TikTok Shop pursuant to which MARKET.live has become a service provider for TikTok Shop and is officially designated as a TikTok Shop Partner (TSP). Under the terms of the partnership, TikTok Shop refers consumer brands, retailers, influencers and affiliates leads to Market.live for a menu of paid services that include, among other things, assistance in onboarding to TikTok and establishing a TikTok store, hosting training...

Lands’ End Announces Fourth Quarter and Full Year Fiscal 2023 Results

Written by Customer Service on March 27, 2024. Posted in Earnings Releases And Operating Results.

Increases Gross Profit by 13.5% and Gross Margin by 550 basis points compared to the Fourth Quarter Fiscal 2022Provides Fiscal 2024 Outlook DODGEVILLE, Wis., March 27, 2024 (GLOBE NEWSWIRE) — Lands’ End, Inc. (NASDAQ: LE) today announced financial results for the fourth quarter and full year of the fiscal year ended February 2, 2024. The Company also provided the first quarter and full year fiscal 2024 outlook. Andrew McLean, Chief Executive Officer, stated, “I am proud of the Lands’ End team’s focus and execution throughout fiscal 2023 as we pursued our solutions-based strategy to introduce newness across the product assortment, generated higher quality sales, significantly enhanced our inventory position and improved our profitability. As a result of these efforts, in the fourth quarter we increased gross profit by 13.5%, improved...

Day: March 27, 2024

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice